HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
TerminatedNCT01125358

A Study in Schizophrenic Patients

Medication studyAges 20–65Multiple countriesSchizophrenia
The study in practice

Understand this study

Who could participate?

This study is for people with schizophrenia. Listed age limits: 20 years to 65 years. Other eligibility criteria apply.

Listed locations
Aichi and 21 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateMay 2010
Recruitment status
Terminated
Enrollment listed in the registry
82
Sponsor
Denovo Biopharma LLC
Sponsor type
Biotech company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Japan, South Korea, Taiwan
Age range
From 20 Years to 65 Years
Official registry ID
NCT01125358
Official title
Show the full official title

A Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 in Patients With DSM-IV-TR Schizophrenia

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Terminated

Aichi, Japan · Kanagawa, Japan · Kumamoto, Japan

18 more locations
  • Kyoto, Japan
  • Nagano, Japan
  • Nagasaki, Japan
  • Nara, Japan
  • Osaka, Japan
  • Saga, Japan
  • Tokyo, Japan
  • Toyama, Japan
  • Yamaguchi, Japan
  • Goyang-si, South Korea
  • Incheon, South Korea
  • Naju, South Korea
  • Seoul, South Korea
  • Suwon, South Korea
  • Yŏngin, South Korea
  • Changhua, Taiwan
  • Hsinchu, Taiwan
  • Taipei, Taiwan
Checked Official study record (opens in a new tab)

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Denovo Biopharma LLC.

Does this study involve medication?

Yes. The study involves medication, including LY2140023 and Placebo.

Who can participate?

This study is for people with schizophrenia. Listed age limits: 20 years to 65 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies